Archives: Speakers

Over the last 25 years, my career has evolved in various roles and I have held senior positions in the pharma/biotech industry and with international CROs. Comprehensive knowledge and experience in Clinical Operations, experience from First in Human up until late stage. Global experience, understanding the nuances of operating in a diverse environment. Strong leadership skills, with experience in a managerial role. Medical background and advanced IT skills in Trial Management Systems, EDC and e-TMF

My aim is to make the people who report to me feel that they are a valued member of a successful team, doing meaningful work in an environment of trust.

Fox Walker has been a defence analyst with GlobalData Plc for the past year. In his role, Fox helps clients navigate the return of great-power competition and understand the ways emerging military technologies are shaping the character of war. Prior to joining GlobalData, Fox earned an MA from the Department of War Studies at King’s College London. Fox is originally from Fort Worth, Texas and graduated from the University of Texas at Austin.

Rob Knight, Atto’s Chief Product & Technology Officer (CPTO), brings a wealth of expertise as a seasoned leader in organisations at the forefront of credit risk. With a strong background in Operations, Product, and Engineering leadership, Rob has championed far-reaching innovation for tech giants and spearheaded impactful digital transformations.

During his time at Experian as the Solution Development & Data Management Director, he played a pivotal role in shaping EMEA propositions and driving technology shifts, particularly within credit bureau services and large-scale transformation projects. Working across many other sectors, Rob has a constant desire to deliver the promise of innovation for the benefit of the business and the consumers enabled within the industry.

Rob brings the best of his experience from broadcast, telecommunications, geospatial, energy and financial services in the quest to transform credit & risk decisioning with open banking technology.

Kris has nearly four decades of experience in the clinical research industry, spanning roles in contract research organizations (CROs), pharmaceutical companies, and academia. Throughout her career, she has worked across a wide range of therapeutic areas, with a strong focus on rare diseases.

As a subject matter expert in rare disease research, Kris has spent significant time collaborating with patient advocacy organizations and patient-led support groups to ensure that the voices of those living with rare conditions are meaningfully represented in every study opportunity. She integrates patient feedback into strategic study insights, driving successful enrollment and retention.

With a long and successful background in clinical operations, Kris brings a comprehensive understanding of all aspects of study execution. She combines this operational expertise with a deep passion for patient-centric research, ensuring success from study inception through completion.

Carl Bjartmar, M.D., Ph.D. CEO and co-founder of BjartmarMed AB. Experienced global pharma and biotech executive providing medical, scientific, and operational consulting expertise to private equity and small/medium companies in drug development, business development and due diligence. Key expertise clinical development within orphan, neuromuscular, neurology and oncology indications. Solid record of global leadership, including two IPOs on Nasdaq OMX, agreed clinical plans with FDA, EMA and PMDA, successful completion of phase I-IV studies, and new drug approvals. Between 2015 and 2018 Chief Medical Officer at Wilson Therapeutics AB, Stockholm, Sweden (acquisition by Alexion Pharmaceuticals in 2018 at 70% premium – USD 850m). Chief Medical Officer at Augustine Therapeutics, Leuven, Belgium. Board member of iCoat Medical AB. More than 30 international publications (peer-reviewed articles, review articles, book chapters).

Kris Booth is the Director of Strategic Partnerships and is responsible for aligning the strategic relationships between CROs, Sponsors, and EmVenio Research. He also assists in the reviewing and implementing of commercial processes in coordination with site operations. Mr. Booth joined EmVenio Research in 2024 with a decade of experience in clinical trial project management and partner relations.

Stephanie Hitchcock is an Director of Project Management at PCM Trials. Stephanie specializes in adapting trial designs for mobile visit services. She is passionate about expanding the use of high-quality, patient-centric models to drive clinical development. Stephanie is an expert in establishing logistics and procedures on a global scale for complex visit schedules and expanding the scope of what mobile visits can support globally.

Professional experience: > 25 years Financial Services Strategy, IT and Operations

Strategy, M&A, DD, PMI, Carve Out, Operations and IT transformation/consolidation, outsourcing/offshoring

Leading EY’s EMEIA Fintech Practice. Innovation Leader for EMEIA Strategy & Transactions and FSO Germany. Leading Financial Services Transaction Strategy & Execution Practice in GSA. Frankfurt Hub Lead of EY’s startup initiative. Curator of EY Start-up Academy, our Frankfurt based early stage accelerator.

Experience: building digital ecosystems, digital banking and insurance, Fintech, Insurtech, payments, cash management, trading, post-trade/securities processing, FX, credit card processing, core banking, back-office consolidation